View Item 

Show simple item record

Evidence-based recommendations for the use of WBC-reduced cellular blood components

dc.contributor.authorRatko, Thomas A.en_US
dc.contributor.authorCummings, Joseph P.en_US
dc.contributor.authorOberman, Harold A.en_US
dc.contributor.authorCrookston, Kendall P.en_US
dc.contributor.authorDeChristopher, Phillip J.en_US
dc.contributor.authorEastlund, D. Teden_US
dc.contributor.authorGodwin, John E.en_US
dc.contributor.authorSacher, Ronald A.en_US
dc.contributor.authorYawn, David H.en_US
dc.contributor.authorMatuszewski, Karl A.en_US
dc.date.accessioned2010-06-01T19:44:52Z
dc.date.available2010-06-01T19:44:52Z
dc.date.issued2001-10en_US
dc.identifier.citationRatko, Thomas A . ; Cummings, Joseph P . ; Oberman, Harold A . ; Crookston, Kendall P . ; DeChristopher, Phillip J . ; Eastlund, D. Ted; Godwin, John E . ; Sacher, Ronald A . ; Yawn, David H . ; Matuszewski, Karl A . (2001). "Evidence-based recommendations for the use of WBC-reduced cellular blood components." Transfusion 41(10): 1310-1319. <http://hdl.handle.net/2027.42/72881>en_US
dc.identifier.issn0041-1132en_US
dc.identifier.issn1537-2995en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/72881
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=11606834&dopt=citationen_US
dc.format.extent95828 bytes
dc.format.extent3109 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.publisherBlackwell Science Incen_US
dc.rights2001 American Association of Blood Banksen_US
dc.subject.otherDHHS = Department of Health and Human Servicesen_US
dc.subject.otherFNHTR(S) = Febrile Nonhemolytic Transfusion Reaction(S)en_US
dc.subject.otherHHV-8 = Human Herpesvirus 8en_US
dc.subject.otherLOS = Length of Stayen_US
dc.subject.otherPC(S) = Platelet Concentrate(S)en_US
dc.subject.otherTRALI = Transfusion-related Acute Lung Injuryen_US
dc.subject.otherUHC = University HealthSystem Consortiumen_US
dc.subject.otherULR = Universal Leukoreductionen_US
dc.subject.otherVATS = Viral Activation Transfusion Studyen_US
dc.subject.otherVCJD = Variant CJDen_US
dc.titleEvidence-based recommendations for the use of WBC-reduced cellular blood componentsen_US
dc.typeArticleen_US
dc.subject.hlbsecondlevelOncology and Hematologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumFrom the Technology Assessment Group, Clinical Practice Advancement Center, University HealthSystem Consortium, Oak Brook, Illinois; the Department of Pathology, University of Michigan, Ann Arbor, Michigan; the Department of Transfusion Medicine and Coagulation, University of New Mexico Health Science Center, Albuquerque, New Mexico; the Blood Bank and Transfusion Medicine, University of Illinois at Chicago Medical Center; and the Hematology Clinical Laboratories, Loyola University Medical Center, Chicago, Illinois; the Division of Transfusion Medicine, Fairview-University Medical Center, Minneapolis, MN; Hoxworth Blood Center, University of Cincinnati Medical Center, Cincinnati, Ohio; and the Department of Pathology, Baylor College of Medicine, Dallas, Texas.en_US
dc.identifier.pmid11606834en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/72881/1/j.1537-2995.2001.41101310.x.pdf
dc.identifier.doi10.1046/j.1537-2995.2001.41101310.xen_US
dc.identifier.sourceTransfusionen_US
dc.identifier.citedreferenceGoodnough LT, Brecher ME, Kanter MH, AuBuchon JP. Transfusion medicine. First of two parts blood transfusion. N Engl J Med 1999; 340: 438 47.en_US
dc.identifier.citedreferenceHogman CF. Improved utilization of blood due to systematic fractionation. Qual Assur Health Care 1990; 2: 207 12.en_US
dc.identifier.citedreferenceCarter TH. Biotechnology, economics, and the business of blood. Biotechnology 1991; 19: 3 30.en_US
dc.identifier.citedreferenceLawrence VA, Birch S, Gafni A. The impact of new clinical guidelines on the North American blood economy. Transfus Med Rev 1994; 8: 232 41.en_US
dc.identifier.citedreferenceLane TA. Leukocyte reduction of cellular blood components. Effectiveness, benefits, quality control, and costs. Arch Pathol Lab Med 1994; 118: 392 404.en_US
dc.identifier.citedreferenceHeaton WA, Rebulla P, Pappalettera M, Dzik WH. A comparative analysis of different methods for routine blood component preparation. Transfus Med Rev 1997; 11: 116 29.en_US
dc.identifier.citedreferenceMiller JP, Mintz PD. The use of leukocyte-reduced blood components. Hematol Oncol Clin North Am 1995; 9: 69 90.en_US
dc.identifier.citedreferenceDzik S, AuBuchon J, Jeffries L, et al. Leukocyte reduction of blood components: public policy and new technology. Transfus Med Rev 2000; 14: 34 52.en_US
dc.identifier.citedreferenceHeddle NM, Blajchman MA. The leukodepletion of cellular blood products in the prevention of HLA-alloimmunization and refractoriness to allogeneic platelet transfusions. Blood 1995; 85: 603 6.en_US
dc.identifier.citedreferenceVamvakas EC. Transfusion-associated cancer recurrence and postoperative infection: meta-analysis of randomized, controlled clinical trials. Transfusion 1996; 36: 175 86.en_US
dc.identifier.citedreferenceHeiss MM. Risk of allogeneic transfusions. Br J Anaesth 1998; 81: 16 9.en_US
dc.identifier.citedreferenceMarquet RL, Busch OR, Jeekel J, et al. Are allogeneic blood transfusions acceptable in elective surgery in colorectal carcinoma? Eur J Cancer 1998; 35: 352 60.en_US
dc.identifier.citedreferenceVamvakas EC. Risk of transmission of Creutzfeldt-Jakob disease by transfusion of blood, plasma, and plasma derivatives. J Clin Apheresis 1999; 14: 135 43.en_US
dc.identifier.citedreferenceThurer RL, Luban NLC, AuBuchon JP, et al. Universal WBC reduction (letter). Transfusion 2000; 6: 751 2.en_US
dc.identifier.citedreferenceBusch M, Chamberland M, Epstein J, et al. Oversight and monitoring of blood safety in the United States. Vox Sang 1999; 77: 67 76.en_US
dc.identifier.citedreferenceGoldbloom R, Battista RN. The periodic health examination: 1. Introduction. CMAJ 1988; 138: 617 8.en_US
dc.identifier.citedreference17. Guide to clinical preventive services an assessment of the effectiveness of 169 interventions. U.S. Preventive Services Task Force. Baltimore: Williams & Wilkins, 1989: xxvii xxxviii.en_US
dc.identifier.citedreferenceCook DJ, Guyatt GH, Laupacis A, et al. Rules of evidence and clinical recommendations on the use of antithrombotic agents. Chest 1992; 102 (4 Suppl): 305S 11S.en_US
dc.identifier.citedreferenceFerguson JH. The NIH Consensus Development Program. The evolution of guidelines. Int J Technol Assess Health Care 1996; 12: 460 74.en_US
dc.identifier.citedreferenceBraunwald E, Antman EM, Beasley JW, et al. ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients with Unstable Angina). J Am Coll Cardiol 2000; 36: 970 1062.en_US
dc.identifier.citedreferenceSchiffer CA, Dutcher JP, Aisner J, et al. A randomized trial of leukocyte-depleted platelet transfusion to modify alloimmunization in patients with leukemia. Blood 1983; 62: 815 20.en_US
dc.identifier.citedreferenceAndreu G, Dewailly J, Leberre C, et al. Prevention of HLA immunization with leukocyte-poor packed red cells and platelet concentrates obtained by filtration. Blood 1988; 72: 964 9.en_US
dc.identifier.citedreferenceSniecinski I, O'Donnell MR, Nowicki B, Hill LR. Prevention of refractoriness and HLA-alloimmunization using filtered blood products. Blood 1988; 71: 1402 7.en_US
dc.identifier.citedreferenceOksanen K, Kekom ki R, Ruutu T, et al. Prevention of alloimmunization in patients with acute leukemia by use of white cell-reduced blood components a randomized trial. Transfusion 1991; 31: 588 94.en_US
dc.identifier.citedreferenceVan Marwijk Kooy M, van Prooijen HC, Moes M, et al. Use of leukocyte-depleted platelet concentrates for the prevention of refractoriness and primary HLA alloimmu-nization: a prospective, randomized trial. Blood 1991; 77: 201 5.en_US
dc.identifier.citedreferenceWilliamson LM, Wimperis JZ, Williamson P, et al. Bedside filtration of blood products in the prevention of HLA alloimmunization a prospective, randomized study. Alloimmunisation Study Group. Blood 1994; 83: 3028 35.en_US
dc.identifier.citedreferenceSintnicolaas K, van Marwijk Kooij M, van Prooijen HC, et al. Leukocyte depletion of random single-donor platelet transfusions does not prevent secondary human leukocyte antigen-alloimmunization and refractoriness: a randomized prospective study. Blood 1995; 85: 824 8.en_US
dc.identifier.citedreference28. Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. The Trial to Reduce Alloimmunization to Platelets Study Group. N Engl J Med 1997; 337: 1861 9.en_US
dc.identifier.citedreferenceVerdonck LF, de Graan-Hentzen YC, Dekker AW, et al. Cytomegalovirus seronegative platelets and leukocyte-poor red blood cells from random donors can prevent primary cytomegalovirus infection after bone marrow transplantation. Bone Marrow Transplant 1987; 2: 73 8.en_US
dc.identifier.citedreferenceDe Graan-Hentzen YCE, Gratama JW, Mudde GC, et al. Prevention of primary cytomegalovirus infection in patients with hematologic malignancies by intensive white cell depletion of blood products. Transfusion 1989; 29: 757 60.en_US
dc.identifier.citedreferenceGilbert GL, Hayes K, Hudson IL, James J. Prevention of transfusion-acquired cytomegalovirus infection in infants by blood filtration to remove leukocytes. The Neonatal Cytomegalovirus Infection Study GroupM. Lancet 1989; 1: 1228 31.en_US
dc.identifier.citedreferenceDe Witte T, Schattenberg A, Van Dijk BA, et al. Prevention of primary cytomegalovirus infection after allogeneic bone marrow transplantation by using leukocyte-poor random blood products from cytomegalovirus-unscreened blood-bank donors. Transplantation 1990; 50: 964 8.en_US
dc.identifier.citedreferenceBowden RA, Slichter SJ, Sayers M, et al. Use of leukocyte-depleted platelets and cytomegalovirus-seronegative red blood cells for prevention of primary cytomegalovirus infection after marrow transplantation. Blood 1991; 78: 246 50.en_US
dc.identifier.citedreferenceEisenfeld L, Silver H, McLaughlin J, et al. Prevention of transfusion-associated cytomegalovirus infection in neonatal patients by the removal of white cells from blood. Transfusion 1992; 32: 205 9.en_US
dc.identifier.citedreferenceVan Prooijen HC, Visser JJ, van Oostendorp WR, et al. Prevention of primary transfusion-associated cytomegalovirus infection in bone marrow transplant recipients by the removal of white cells from blood components with high-affinity filters. Br J Haematol 1994; 87: 144 7.en_US
dc.identifier.citedreferenceBowden RA, Slichter SJ, Sayers M, et al. A comparison of filtered leukocyte-reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion-associated CMV infection after marrow transplant. Blood 1995; 86: 3598 603.en_US
dc.identifier.citedreferenceNarvios AB, Przepiorka D, Tarrand J, et al. Transfusion support using filtered unscreened blood products for cytomegalovirus-negative allogeneic marrow transplant recipients. Bone Marrow Transplant 1998; 22: 575 7.en_US
dc.identifier.citedreferencePreiksaitis JK. The cytomegalovirus- safe blood product: is leuko reduction equivalent to antibody screening? Transfus Med Rev 2000; 14: 112 36.en_US
dc.identifier.citedreferenceCollier AC, Kalish LA, Busch MP, et al. Leukocyte-reduced red blood cell transfusions in patients with anemia and human immunodeficiency virus infection: the Viral Activation Transfusion Study: a randomized controlled trial. JAMA 2001; 285: 1592 601.en_US
dc.identifier.citedreferenceJensen LS, Andersen AJ, Christiansen PM, et al. Postoperative infection and natural killer cell function following blood transfusion in patients undergoing elective colorectal surgery. Br J Surg 1992; 79: 513 6.en_US
dc.identifier.citedreferenceHoubiers JG, Brand A, van de Watering LM, et al. Randomised controlled trial comparing transfusion of leucocyte-depleted or buffy-coat-depleted blood in surgery for colorectal cancer. Lancet 1994; 344: 573 8.en_US
dc.identifier.citedreferenceJensen LS, Kissmeyer-Nielsen P, Wolff B, Qvist N. Randomised comparison of leucocyte-depleted versus buffy-coat-poor blood transfusion and complications after colorectal surgery. Lancet 1996; 348: 841 5.en_US
dc.identifier.citedreferenceTartter PI, Mohandas K, Azar P, et al. Randomized trial comparing packed red cell blood transfusion with and without leukocyte depletion for gastrointestinal surgery. Am J Surg 1998; 176: 462 6.en_US
dc.identifier.citedreferenceVan de Watering LM, Hermans J, Houbiers JG, et al. Beneficial effects of leukocyte depletion of transfused blood on postoperative complications in patients undergoing cardiac surgery: a randomized clinical trial. Circulation 1998; 97: 562 8.en_US
dc.identifier.citedreferenceVamvakas EC, Blajchman MA. Deleterious clinical effects of transfusion-associated immunomodulation: fact or fiction? Blood 2001; 97: 1180 95.en_US
dc.identifier.citedreferenceVamvakas EC, Blajchman MA. Universal WBC reduction: the case for and against. Transfusion 2001; 41: 691 712.en_US
dc.identifier.citedreferenceAnderson KC, Weinstein HJ. Transfusion-associated graft-versus-host disease. N Engl J Med 1990; 323: 315 21.en_US
dc.identifier.citedreferenceHeddle NM. Pathophysiology of febrile nonhemolytic transfusion reactions. Curr Opin Hematol 1999; 6: 420 6.en_US
dc.identifier.citedreferenceHeddle NM, Klama L, Singer J, et al. The role of the plasma from platelet concentrates in transfusion reactions. N Engl J Med 1994; 331: 625 8.en_US
dc.identifier.citedreferenceHeddle NM, Klama L, Meyer R, et al. A randomized controlled trial comparing plasma removal with white cell reduction to prevent reactions to platelets. Transfusion 1999; 39: 231 8.en_US
dc.identifier.citedreferenceNess PM. Transfusion medicine: an overview and update. Clin Chem 2000; 46: 1270 6.en_US
dc.identifier.citedreferenceGlynn SA, Kleinman SH, Schreiber GB, et al. Trends in incidence and prevalence of major transfusion-transmissible viral infections in US blood donors, 1991 to 1996. Retrovirus Epidemiology Donor Study (REDS). JAMA 2000; 284: 229 35.en_US
dc.identifier.citedreferenceSchreiber GB, Busch MP, Kleinman SH, Korelitz JJ. The risk of transfusion-transmitted viral infections. The Retrovirus Epidemiology Donor Study. N Engl J Med 1996; 334: 1685 90.en_US
dc.identifier.citedreferenceHolland PV. Viral infections and the blood supply (editorial). N Engl J Med 1996; 334: 1734 5.en_US
dc.identifier.citedreferenceKruskall MS. The perils of platelet transfusions (editorial). N Engl J Med 1997; 337: 1914 5.en_US
dc.identifier.citedreferenceKlein HG. Will blood transfusion ever be safe enough? (editorial). JAMA 2000; 284: 238 40.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
j.1537-2995.2001.41101310.x.pdf
Size:
93.58KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.